# Mitral Valve Prolapse

Mitral valve prolapse requires management driven by mitral regurgitation burden, left-heart remodeling, symptoms, atrial fibrillation, pulmonary pressure, and a distinct ventricular arrhythmia phenotype rather than leaflet displacement alone.

**Clinical question:** How should clinicians evaluate mitral valve prolapse for consequential regurgitation, ventricular remodeling, and ventricular arrhythmia risk?

Updated: 2026-09-15T22:51:34.517996+00:00

## What matters in practice
- Confirm MVP by systolic displacement of one or both leaflets >2 mm into the left atrium on echocardiography; do not equate MVP anatomy with clinically important mitral regurgitation. [1][7][8]
- In primary MR, LVEF ≤60%, LV end-systolic diameter ≥40 mm, left atrial systolic volume index >60 mL/m², recent-onset atrial fibrillation, and pulmonary hypertension identify adverse remodeling or prognosis that should change surveillance and valve-intervention discussions. [5]
- Grade MR with an integrated echocardiographic assessment; pulmonary-vein systolic flow reversal, pulmonary artery systolic pressure >50 mm Hg without another cause, and mitral E-wave velocity >1.2–1.5 m/s support severe MR. [5]
- Do not use MR severity alone to assess sudden-death risk: bileaflet, multisegment prolapse, mitral annular disjunction, complex ventricular ectopy, and papillary-muscle fibrosis characterize an arrhythmic MVP phenotype. [2][9][24]
- MVP surgery is directed primarily by severe primary MR and its ventricular or clinical consequences; intervention before symptom onset or LVEF/LV end-systolic dimension thresholds has been associated with better survival and functional outcomes. [5]

## Confirm MVP and determine whether regurgitation is primary and consequential

The first decision is whether leaflet anatomy has produced clinically important primary MR.

Diagnose MVP on transthoracic echocardiography (TTE) by systolic displacement of part of one or both mitral leaflets into the left atrium; a >2-mm displacement criterion is used in echocardiographic studies. [1][7][8] Document which leaflet segments prolapse, whether involvement is bileaflet or multisegmental, leaflet morphology, and the MR mechanism rather than reporting “MVP” as a stand-alone finding.

At the index evaluation, obtain history, examination, ECG, and a comprehensive TTE that reports MR severity, LV size and systolic function, left atrial size, and estimated pulmonary pressure. This separates uncomplicated MVP from primary degenerative MR with volume-overload consequences and identifies patients whose referral should focus on repair feasibility. [4][5]

Use an integrated rather than a single-parameter MR assessment. A dense triangular continuous-wave Doppler MR profile, well-aligned MR velocity <4.5 m/s suggesting elevated left atrial pressure, otherwise unexplained LA or LV dilation, pulmonary artery systolic pressure >50 mm Hg, pulmonary-vein systolic flow reversal, and dominant mitral inflow E-wave velocity >1.2–1.5 m/s in the absence of mitral stenosis support severe MR. [5]
- A soft or incomplete continuous-wave MR jet, normal pulmonary artery systolic pressure, or MR occupying <30% of systole supports mild MR. [5]
- When chamber enlargement, Doppler findings, and apparent jet severity disagree, avoid management decisions based on jet appearance alone; reconcile severity with the integrated TTE assessment. [4][5]

*Echocardiographic findings that change classification or urgency in MVP-associated MR. [5]*

| Finding | Interpretation | Clinical consequence |
| --- | --- | --- |
| Leaflet systolic displacement >2 mm into the left atrium | Supports MVP anatomy. [7][8] | Characterize leaflet segments and assess MR mechanism and severity. |
| Pulmonary-vein systolic flow reversal | Supports severe MR. [5] | Evaluate for severe primary MR and valve-intervention candidacy. |
| Pulmonary artery systolic pressure >50 mm Hg without another cause | Supports severe MR and identifies adverse hemodynamic consequence. [5] | Accelerate comprehensive valve assessment and intervention discussion. |
| Dilated LA or LV without another cause | Supports important chronic MR. [5] | Track remodeling; determine whether severe-MR intervention thresholds are present. |

## Use ventricular and clinical consequences to time referral for primary MR intervention

Severe primary MR is the management branch that most directly determines need for mitral intervention.

For MVP with severe primary MR, treat LVEF ≤60% or LV end-systolic diameter ≥40 mm as adverse LV thresholds. In chronic MR, an LVEF that appears numerically preserved can still reflect declining contractile reserve; therefore, do not defer a valve-team assessment until EF is frankly reduced. [5]

Recent-onset atrial fibrillation, pulmonary hypertension, left atrial systolic volume index >60 mL/m², EROA, and flail leaflet are prognostically important features in primary MR. Their presence should prompt reassessment of MR severity and timely evaluation of intervention strategy rather than surveillance based only on symptom status. [5]

When surgery is selected for degenerative MVP with severe MR, assess the likelihood of durable mitral repair as part of procedural planning. Evidence summarized in the ACC pathway associates surgery before symptoms or before LVEF ≤60% and LV end-systolic diameter ≥40 mm are reached with improved survival and functional outcomes. [5]
- Refer symptomatic severe primary MR for valve-intervention assessment after confirming integrated severe MR and defining valve anatomy. [5]
- Refer asymptomatic severe primary MR when LVEF is ≤60% or LV end-systolic diameter is ≥40 mm. [5]
- Reassess for intervention when severe MR is accompanied by new atrial fibrillation, pulmonary hypertension, marked LA enlargement, or a flail leaflet. [5]

*Findings in primary MR associated with worse prognosis and a lower threshold for intervention assessment. [5]*

| Trigger | Threshold or feature | Next step |
| --- | --- | --- |
| LV systolic function | LVEF ≤60%. [5] | Valve-team assessment for severe primary MR. |
| LV remodeling | LV end-systolic diameter ≥40 mm. [5] | Valve-team assessment for severe primary MR. |
| Left atrial remodeling | LA systolic volume index >60 mL/m². [5] | Reconfirm MR severity and reassess timing of intervention. |
| Rhythm or pressure consequence | Recent-onset AF or pulmonary hypertension. [5] | Reassess severe MR and accelerate intervention discussion. |

## Screen for arrhythmic MVP independently of MR severity

A small MVP subgroup has ventricular-arrhythmic risk that is not explained by MR burden alone.

Ask specifically about unexplained syncope, exertional presyncope, sustained palpitations, documented ventricular tachycardia, and out-of-hospital arrest. In patients with concerning symptoms, abnormal ECG findings, or high-risk valve morphology, obtain ambulatory rhythm monitoring to define ventricular ectopy burden, complexity, and sustained ventricular arrhythmia; arrhythmic MVP is characterized by MVP with or without mitral annular disjunction plus frequent or complex ventricular ectopy or sustained ventricular arrhythmia when another arrhythmic substrate is not identified. [3][24]

Bileaflet and extensive multisegment prolapse are prominent in reported malignant MVP cohorts. Mitral annular disjunction should be specifically sought on imaging because it may accompany the arrhythmic phenotype and should not be dismissed as an incidental descriptive finding in a patient with ventricular ectopy or syncope. [2][7][24]

Escalate imaging evaluation when the rhythm phenotype or valve morphology is concerning. Papillary-muscle fibrosis was present histologically in all cases in one sudden-death series with arrhythmic MVP, linking ventricular arrhythmia assessment to a search for myocardial substrate rather than to MR grading alone. [9] Cardiac magnetic resonance is clinically relevant when it can identify myocardial fibrosis or clarify anatomy in a patient with complex ventricular arrhythmias. [6][11]

Complex ectopy or sustained ventricular arrhythmia requires evaluation for competing structural, ischemic, inherited, and electrical causes before attributing the rhythm disorder to MVP. The absence of another well-defined arrhythmic substrate is part of the reported arrhythmic-MVP construct. [24]
- Do not reassure solely on the basis of nonsevere MR when bileaflet prolapse, mitral annular disjunction, syncope, or complex ventricular ectopy is present. [2][3][24]
- Use serial echocardiography and ambulatory rhythm assessment in patients with suspected arrhythmic MVP rather than a one-time MR severity assessment. [3]
- Direct patients with sustained ventricular arrhythmia, unexplained syncope plus high-risk MVP features, or prior cardiac arrest to electrophysiology and structural-heart evaluation. [24]

### Interpretation of phenotype markers

No single anatomic feature establishes arrhythmic MVP. The actionable pattern is concordance among high-risk morphology, ventricular ectopy or sustained arrhythmia, and evidence of myocardial substrate. Bileaflet involvement was reported in 70% of arrhythmic MVP sudden-death cases, but risk assessment must integrate rhythm and imaging findings rather than use bileaflet prolapse alone as a deterministic marker. [9][3]

*Features that should trigger an arrhythmic MVP evaluation. [2][3][7][9][24]*

| Trigger | Test or finding to obtain | Interpretation and next action |
| --- | --- | --- |
| Syncope, sustained palpitations, or known ventricular arrhythmia | Ambulatory rhythm monitoring. [3][24] | Define frequent, complex, or sustained ventricular arrhythmia; evaluate for other arrhythmic substrates. [24] |
| Bileaflet or multisegment MVP | Focused echo characterization; assess for mitral annular disjunction. [2][7] | Do not rely on MR severity alone for risk assessment. [3] |
| Complex ventricular ectopy with MVP | Cardiac magnetic resonance when assessment of myocardial substrate will change management. [6][11] | Look for fibrosis, including papillary-muscle involvement described in arrhythmic MVP. [9][11] |
| Sustained ventricular arrhythmia without another substrate | Electrophysiology and structural-heart assessment. [24] | Fits the reported arrhythmic-MVP phenotype when MVP is present with or without mitral annular disjunction. [24] |

## Match surveillance intensity to MR progression and arrhythmic phenotype

Follow-up should track the complication most likely to change management: MR remodeling or ventricular arrhythmia.

For MVP without significant MR or adverse chamber findings, the clinically useful surveillance target is interval change in MR severity, LV size and function, LA size, pulmonary pressure, symptoms, and rhythm. Repeat comprehensive echocardiography when symptoms change, a murmur changes, atrial fibrillation develops, or prior imaging shows progressive MR or remodeling; severe MR requires closer reassessment because intervention thresholds are defined by LV and clinical consequences. [4][5]

In suspected arrhythmic MVP, surveillance should include serial echocardiography and ambulatory rhythm assessment rather than MR-focused follow-up alone. Escalate promptly for new syncope, increasing palpitations, complex ectopy, or sustained ventricular arrhythmia. [3][24]

MVP alone is not an indication for antithrombotic therapy for primary stroke prevention. Antiplatelet therapy described for secondary prevention after ischemic stroke or TIA is not a substitute for determining the actual embolic mechanism or for managing atrial fibrillation according to its separate indication. [14]
- At each review, document interval dyspnea, exercise decline, palpitations, presyncope or syncope, and atrial fibrillation; each may signal progression requiring repeat imaging or rhythm monitoring. [4][5][24]
- For new atrial fibrillation or pulmonary hypertension in a patient with MR, reassess severity and intervention timing rather than attributing the finding to MVP alone. [5]
- Evaluate fever with a new or changed regurgitant murmur or embolic syndrome for infective endocarditis, because MVP can be associated with bacterial endocarditis. [12]

*Follow-up events that should trigger reassessment in MVP. [3][4][5][12][24]*

| Interval event | Immediate reassessment | Management implication |
| --- | --- | --- |
| New exertional limitation or heart-failure symptoms | Comprehensive TTE for MR severity, LV function, chamber dimensions, and pulmonary pressure. [4][5] | Determine whether severe primary MR and intervention triggers are present. |
| New atrial fibrillation | ECG confirmation and comprehensive MR reassessment. [5] | Recent-onset AF is an adverse prognostic feature in primary MR. [5] |
| Syncope or complex palpitations | Ambulatory rhythm monitoring; assess morphology and consider CMR for substrate. [3][6][24] | Evaluate for arrhythmic MVP and competing arrhythmic causes. |
| Fever with embolic features or changed murmur | Evaluate for infective endocarditis. [12] | MVP is associated with bacterial endocarditis. [12] |

## Common questions

### Does nonsevere mitral regurgitation exclude malignant MVP?

No. A small MVP subgroup has increased sudden-death risk independent of MR severity; assess symptoms, ambulatory rhythm findings, bileaflet or multisegment prolapse, mitral annular disjunction, and myocardial fibrosis when clinically indicated. [2][3][5][9][24]

### What LVEF should prompt concern in chronic primary MR from MVP?

An LVEF ≤60% is an adverse threshold in primary MR, as is LV end-systolic diameter ≥40 mm; either finding warrants valve-intervention assessment when severe primary MR is present. [5]

## References
1. Mitral-Valve Repair for Mitral-Valve Prolapse — www.nejm.org — https://www.nejm.org/doi/full/10.1056/NEJMct0806111
2. Mitral valve and left ventricular features in malignant ... - Open Heart — openheart.bmj.com — https://openheart.bmj.com/content/5/2/e000925
3. Arrhythmogenic Mitral Valve Prolapse: Looking Beyond ... - JACC — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jaccas.2026.109661
4. Left atrial size predicts outcome in severe but asymptomatic mitral regurgitation | Scientific Reports — www.nature.com — https://www.nature.com/articles/s41598-023-31163-0
5. 2020 Focused Update of the 2017 ACC Expert Consensus Decision Pathway on the Management of Mitral Regurgitation: A Report of the American College of Cardiology Solution Set Oversight Committee — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2020.02.005
6. Unlocking the Mysteries of Arrhythmic Mitral Valve Prolapse by CMR ... — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jcmg.2021.02.030
7. Functional Implication of Mitral Annular Disjunction in Mitral Valve ... — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jcmg.2016.11.022
8. Prevalence and characteristics of mitral valve prolapse in military young adults in Taiwan of the CHIEF Heart Study | Scientific Reports — www.nature.com — https://www.nature.com/articles/s41598-021-81648-z
9. Arrhythmic Mitral Valve Prolapse and Sudden Cardiac Death — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/circulationaha.115.016291
10. Mitral Valve Prolapse, Ventricular Arrhythmias, and Sudden Death — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.034075
11. Mitral Valve Prolapse Induces Regionalized Myocardial Fibrosis — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/JAHA.121.022332
12. Epidemiology and Pathophysiology of Mitral Valve Prolapse — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/circulationaha.113.006702
13. Mitral Valve Prolapse Patients with Less than Moderate Mitral Regurgitation Exhibit Early Cardiac Chamber Remodeling - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0894731720300389
14. Mitral Valve Prolapse - an overview | ScienceDirect Topics — www.sciencedirect.com — https://www.sciencedirect.com/topics/medicine-and-dentistry/mitral-valve-prolapse
15. Mitral Valve Regurgitation in the Contemporary Era: Insights Into Diagnosis, Management, and Future Directions — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1936878X18301086
16. Arrhythmic Mitral Valve Prolapse: JACC Review Topic of the Week — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0735109718386923
17. International Session Poster - Obstetrics and Gynecology — obgyn.onlinelibrary.wiley.com — https://obgyn.onlinelibrary.wiley.com/doi/pdf/10.1111/jog.13207
18. Arrhythmogenic mitral valve prolapse—a systematic review of ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1002/joa3.70108
19. Cardiac CT Angiography for the Diagnosis of Mitral Valve Prolapse — pubs.rsna.org — https://pubs.rsna.org/doi/10.1148/radiol.2541090393
20. ICD-10 and Related Health Statistical Classification of Diseases and ... — www.cdc.gov — https://www.cdc.gov/nchs/nvss/manuals/2025/2e-vol1-2025.html
21. Health Supervision for Children With Marfan Syndrome | Pediatrics — pediatrics.aappublications.org — https://pediatrics.aappublications.org/content/early/2013/09/24/peds.2013-2063.abstract
22. Cardiac Computed Tomography for Prosthetic Heart Valve ... — pubs.rsna.org — https://pubs.rsna.org/doi/10.1148/ryct.250231
23. [PDF] Hysterectomy Surveillance — United States, 1994–1999 Malaria ... — stacks.cdc.gov — https://stacks.cdc.gov/view/cdc/13513/cdc_13513_DS1.pdf
24. Protocol — cdn.clinicaltrials.gov — https://cdn.clinicaltrials.gov/large-docs/30/NCT05631730/Prot_002.pdf

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.